EN BLINDAD UTVÄRDERING AV IBT:S CONNECTION STUDY – “SUSTAINED FEEDING TOLERANCE” (SFT) KORRELERAR MED KLINISKA UTFALL
December 06, 2021 13:47 ET
|
Infant Bacterial Therapeutics AB
En blind utvärdering av IBTs Connection Study kommer att presenteras av Professor Josef Neu, University of Florida, vid 2021 Hot Topics in Neonatology® den 6 december 2021. Utvärderingen avslöjar att...
A Blinded Evaluation of the Connection Study – Sustained Feeding Tolerance (SFT) Correlates to Clinical Outcomes
December 06, 2021 13:47 ET
|
Infant Bacterial Therapeutics AB
A blinded evaluation of IBT’s Connection Study will be presented by Professor Josef Neu, University of Florida, at the 2021 Hot Topics in Neonatology® on December 6, 2021. The evaluation reveals that...
Valberedning utsedd inför årsstämman 2022 i Infant Bacterial Therapeutics (IBT).
October 29, 2021 10:15 ET
|
Infant Bacterial Therapeutics AB
Stockholm, 29 oktober 2021. Styrelsens ordförande i IBT har etablerat en valberedning inför årsstämman, som avses hållas den 4 maj 2022. Ledamöterna har utsetts av IBTs, i förhållande till röstetalet,...
Nomination Committee appointed for the 2022 Annual General Meeting (AGM) in Infant Bacterial Therapeutics (IBT).
October 29, 2021 10:15 ET
|
Infant Bacterial Therapeutics AB
Stockholm, October 29, 2021. The Chairman of IBT has established a Nomination Committee for the AGM, which is planned to be held on May 4, 2022. The Nomination Committee is composed, according to...
Infant Bacterial Therapeutics AB (publ), (IBT) Delårsrapport 1 januari – 30 september 2021
October 29, 2021 02:00 ET
|
Infant Bacterial Therapeutics AB
VD kommenterar Som bekant genomför IBT en stor fas III-studie (“The Connection Study”) vilket är den sista studien i vårt kliniska utvecklingsprogram med läkemedelskandidaten IBP-9414, som...
Infant Bacterial Therapeutics AB (publ), Interim report January 1-September 30, 2021
October 29, 2021 02:00 ET
|
Infant Bacterial Therapeutics AB
Infant Bacterial Therapeutics AB (publ), Interim report January 1-September 30, 2021 Message from the CEO As is well known, IBT is conducting a large phase III study ("The Connection Study"), the...
IBT har uppnått ytterligare en milstolpe i sin fas III studie.
September 30, 2021 13:00 ET
|
Infant Bacterial Therapeutics AB
Infant Bacterial Therapeutics (IBT) kan idag meddela att företaget nu har uppnått ytterligare en viktig milstolpe genom att ha rekryterat 600 barn i den pågående kliniska fas III-studien av IBP-9414....
Next recruitment milestone reached in IBT’s Phase III Study.
September 30, 2021 13:00 ET
|
Infant Bacterial Therapeutics AB
Infant Bacterial Therapeutics (IBT) announces that the company has reached the next important milestone after recruiting 600 premature infants in the ongoing Clinical Phase III study of IBP-9414....
Efter säkerhetsgranskning har rekryteringen av de minsta barnen i the Connection study återupptagits.
September 22, 2021 16:30 ET
|
Infant Bacterial Therapeutics AB
Efter säkerhetsgranskning har rekryteringen av de minsta barnen i the Connection study återupptagits. Efter att säkerhetsgranskningen som utförts av Data Monitoring Committee (DMC) har slutförts kan...
After safety review The Connection study is now again open to recruit the smallest infants.
September 22, 2021 16:30 ET
|
Infant Bacterial Therapeutics AB
After safety review The Connection study is now again open to recruit the smallest infants. Following the completion of the DMC (Data Monitoring Committee) safety review, IBT is pleased to announce...